Bank of America just raised its EUR/USD forecast
Investing.com - TD Cowen has maintained its Buy rating and $106.00 price target on Medtronic , Inc. (NYSE:MDT), a $118.65 billion medical technology leader, following its fiscal first quarter 2026 results. According to InvestingPro data, the stock is trading near its 52-week high with a solid 3.06% dividend yield.
Medtronic reported adjusted revenue of $8.54 billion with underlying organic growth of 4.8%, exceeding the consensus target of $8.38 billion. By region, organic sales growth in the US was 3.5%, while international growth reached 6.1%. The company’s overall revenue growth of 3.62% and robust gross margin of 65.39% underscore its market strength. InvestingPro subscribers can access 8 additional key insights about Medtronic’s financial health and growth prospects.
The company posted non-GAAP earnings per share of $1.26, surpassing both the Street estimate of $1.23 and the top end of its guidance range of $1.22-$1.24. Non-GAAP gross margin came in at 65.1%, slightly above consensus expectations of 64.9%.
Medtronic outperformed sales targets in three of its four divisions, with Cardiovascular revenue totaling $3.29 billion (up 7.0% organically), Medical (TASE:BLWV) Surgical sales reaching $2.08 billion (up 2.4% organically), and Diabetes sales hitting $721 million (up 7.9% organically).
Neuroscience was the only segment to fall short of expectations, with revenue of $2.42 billion just below the $2.43 billion Street estimate, though still reflecting 3.1% organic sales growth.
In other recent news, Medtronic PLC (BVMF:MDTC34) reported its first-quarter fiscal 2026 earnings, surpassing Wall Street expectations. The company achieved an adjusted earnings per share (EPS) of $1.26, exceeding the forecasted $1.23. Revenue also outperformed projections, reaching €8.6 billion compared to the anticipated €8.38 billion. Despite these positive financial results, the company’s stock experienced a decline in premarket trading. The stock closed at $87.97, down from its previous close of $92.81. These developments come amidst a backdrop of fluctuating market conditions. Investors and analysts continue to monitor Medtronic’s performance closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.